Dr. Stanislav Tiazhelnikov

Early development of small molecules (from MTS and HCS to LO, ADMET in vitro). Kinase, ATPase, PPi, cell-based assays for drug screening and characterisation. Writing SOPs, qualification of equipment and methods. Experience in the GxP environment - organisation of processes, creation and maintaining documentation. PO in phenotypic drug discovery and toxicity platform on 3D cell culture (spheroids, tumoroids, organoids) and in-house active protein production (wheat germ, baculovirus)

Developed and provided of new cell-based functional tests – flow cytometry: cytotoxicity, proliferation, TU, phenotyping, cytokine release; fluorescent microscopy: sprouting, tubing Supported analytics for gene therapy development: CAR-T (CD19, CD38, CD269), AAV (AMD) and LV vectors Implement strategies for controlling gene-engineered T cells at various stages of the process Initiated de novo project for Haemophilia A treatment based on targeted LV.

Launched the iMet project: http://pharm-pht.com/ Developed HPLC MS protocols and huge knowledge base on pharmacokinetics and drug interactions for issuing recommendations on the selection of individual therapy Raised $300 000 from private and governmental funds in 2 years

Launched the project for HIV treatment and raised $1.7 million for R&D Established R&D partnership with University of Maryland, Tel Aviv University and Oxford University Taught MBA courses at National Research University Higher School of Economics (is one of the 10 top Russian Universities)

Developed cell-based tests: ADMET, DMPK, Provided preclinical testing of the 3 leader substances: Pyron - selective COX-2 inhibitor, Glytiphen - GSK3B inhibitor, Chlordion – antifungal agent. Researched on human cell lines in/at such areas as cancer, Alzheimer's disease and diabetes mellitus

Developed protocols for new drugs and generics quality control, SOP writing Conducted qualitative and quantitative analysis using GC MS, HPLC MS, Plate readers, ELISA, spectrophotometry, and confocal microscopy